Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Parkinson's Disease: Treatment

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...

Parkinson's Disease: Overview

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...

Neural Regulation

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Extensive dysautonomia in early-stage multiple system atrophy reflects survival differences: insights from data-driven subtypes.

Journal of neurology·2026

Same author

Reply: Genetically proxied GLP1R expression does not predict exenatide response in the Exenatide-PD3 trial.

Brain : a journal of neurology·2026

Same author

Allergic disease as a risk factor for Parkinson's disease: a possible role of eosinophil.

NPJ Parkinson's disease·2026

Same author

Digital Technology for Sleep Symptoms in Parkinson's Disease: A Scoping Review.

Journal of movement disorders·2026

Same author

GLP1R expression and parkinson's disease and related disorders in GLP-1RA-treated type 2 diabetes.

Brain : a journal of neurology·2026

Same author

Longitudinal resting-state EEG-based modeling predicts phenoconversion and delineates heterogeneity in isolated REM sleep behavior disorder.

Research square·2026

Search research articles

Related Experiment Video

Updated: May 7, 2026

A Novel Approach to Assess Motor Outcome of Deep Brain Stimulation Effects in the Hemiparkinsonian Rat: Staircase and Cylinder Test

A Novel Approach to Assess Motor Outcome of Deep Brain Stimulation Effects in the Hemiparkinsonian Rat: Staircase and Cylinder Test

Published on: May 31, 2016

Parkin mutation and deep brain stimulation outcome.

Hee Jin Kim¹, Ji Young Yun², Young-Eun Kim²

¹Department of Neurology, Konkuk University Medical Center, Seoul, Republic of Korea.

Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia

|September 25, 2013

Summary

Deep brain stimulation (DBS) shows similar therapeutic effects for Parkinson's disease patients with and without parkin mutations. This study found no significant differences in outcomes, suggesting DBS is effective regardless of parkin mutation status.

Keywords:

Deep brain stimulation Neurophysiology Parkin Parkinson’s disease Subthalamic nucleus

More Related Videos

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation

Published on: July 16, 2014

Intra-Operative Behavioral Tasks in Awake Humans Undergoing Deep Brain Stimulation Surgery

Intra-Operative Behavioral Tasks in Awake Humans Undergoing Deep Brain Stimulation Surgery

Published on: January 6, 2011

Related Experiment Videos

Last Updated: May 7, 2026

A Novel Approach to Assess Motor Outcome of Deep Brain Stimulation Effects in the Hemiparkinsonian Rat: Staircase and Cylinder Test

A Novel Approach to Assess Motor Outcome of Deep Brain Stimulation Effects in the Hemiparkinsonian Rat: Staircase and Cylinder Test

Published on: May 31, 2016

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation

Published on: July 16, 2014

Intra-Operative Behavioral Tasks in Awake Humans Undergoing Deep Brain Stimulation Surgery

Intra-Operative Behavioral Tasks in Awake Humans Undergoing Deep Brain Stimulation Surgery

Published on: January 6, 2011

Area of Science:

Neurology
Neurosurgery
Genetics

Background:

Parkinson's disease (PD) patients with parkin mutations often exhibit good levodopa response and dyskinesia.
Deep brain stimulation (DBS) is a potential treatment, but outcomes in parkin mutation carriers are not well-documented.

Purpose of the Study:

To compare the surgical outcomes of subthalamic nucleus DBS in early-onset Parkinson's disease patients with and without parkin mutations.

Main Methods:

Screened 14 early-onset PD patients undergoing DBS for parkin mutations.
Assessed surgical outcomes pre- and post-operatively (2-5 years) using the Unified Parkinson's Disease Rating Scale (UPDRS) and levodopa equivalent daily doses.

Main Results:

No significant differences in UPDRS improvements (parts II, III, IV) or reduction in levodopa dosage between patients with and without parkin mutations.
Patients with homozygote/compound heterozygote parkin mutations were younger at onset and had longer disease duration.

Conclusions:

Subthalamic nucleus DBS offers comparable therapeutic benefits for Parkinson's disease patients irrespective of their parkin mutation status.
DBS efficacy is not significantly influenced by the presence of parkin mutations in early-onset PD.